|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...6263646566676869707172...156157» |
- Trial completion: Efficacy Study of Andrographis Paniculata Purified Standardized Extract (ApE) in Patients With Multiple Sclerosis (MS) (clinicaltrials.gov) - Jun 18, 2015
P2, N=30, Completed, Sponsor: Universidad Austral de Chile
Active, not recruiting --> Completed
- Januvia (sitagliptin) / Merck (MSD)
Biomarker, Trial completion: Ketosis-Prone Diabetes Mellitus (KPDM): Metformin Versus Sitagliptin Treatment (clinicaltrials.gov) - Jun 18, 2015
P4, N=48, Completed, Sponsor: Dawn Smiley MD
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| rofecoxib (TRM-201) / Tremeau Pharma
Trial completion: A Study of Rofecoxib Versus Naproxen in the Treatment of Chinese Patient With Rheumatoid Arthritis (0966-231) (clinicaltrials.gov) - Jun 18, 2015
P4, N=150, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Terminated --> Completed
- New trial: ENHANCE: MS Symptom Management Study (clinicaltrials.gov) - Jun 18, 2015
P=N/A, N=30, Not yet recruiting, Sponsor: University of Washington
- ||||| Lantus (insulin glargine) / Sanofi, Admelog (insulin lispro biosimilar) / Sanofi
Enrollment closed: SORELLA1: Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine (clinicaltrials.gov) - Jun 18, 2015
P3, N=480, Active, not recruiting, Sponsor: Sanofi
Terminated --> Completed Recruiting --> Active, not recruiting
- aspirin / Generic mfg.
Trial primary completion date: Aspirin Resistance in Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - Jun 17, 2015
P1, N=120, Active, not recruiting, Sponsor: Vanderbilt University
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2014 --> Dec 2016
- ||||| New P2 trial: A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis (clinicaltrials.gov) - Jun 17, 2015
P2, N=62, Not yet recruiting, Sponsor: Grifols Therapeutics Inc.
- PF530 (interferon beta-1b biosimilar) / Ligand
New P1 trial: Comparison Study of PF530 and Betaferon in Healthy Subjects (clinicaltrials.gov) - Jun 17, 2015
P1, N=12, Recruiting, Sponsor: Pfenex, Inc
- | BioChaperone lispro (ultra fast-acting insulin analog) / Adocia
Trial completion: Blood Glucose Control With BioChaperone Insulin Lispro Compared to Insulin Lispro (Humalog (clinicaltrials.gov) - Jun 17, 2015
P1, N=38, Completed, Sponsor: Adocia
Trial primary completion date: Dec 2014 --> Dec 2016 Recruiting --> Completed
- | HinsBet (human insulin) / Adocia
Trial completion: A Double-blinded, Randomised, Three-period Crossover Euglycaemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Human Insulin, Human Insulin (Huminsulin (clinicaltrials.gov) - Jun 17, 2015
P1/2, N=38, Completed, Sponsor: Adocia
Recruiting --> Completed Recruiting --> Completed
- |||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion, Enrollment change, Real-world evidence, Real-world: Good EULAR Response In Patients With Early Rheumatoid Arthritis (clinicaltrials.gov) - Jun 17, 2015
P4, N=80, Completed, Sponsor: Pfizer
Recruiting --> Completed Recruiting --> Completed | N=150 --> 80
- New trial: HORTIM: Interest of Medical Imaging in the Diagnostic Strategy Vis a Vis a Suspected Horton Disease (clinicaltrials.gov) - Jun 16, 2015
P=N/A, N=45, Recruiting, Sponsor: Fondation Ophtalmologique Adolphe de Rothschild
- | dimethyl fumarate / Generic mfg.
New P4 trial: PROMPT: Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis (clinicaltrials.gov) - Jun 16, 2015
P4, N=150, Not yet recruiting, Sponsor: Biogen Italia srl.
- | Hulio (adalimumab biosimilar) / Viatris, Fujifilm Kyowa Kirin Biologics
Enrollment open: ARABESC-OLE: A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients (clinicaltrials.gov) - Jun 16, 2015
P3, N=480, Recruiting, Sponsor: Fujifilm Kyowa Kirin Biologics Co., Ltd.
Recruiting --> Completed | N=150 --> 80 Not yet recruiting --> Recruiting
- | namilumab (IZN-101) / Amgen, Izana Biosci
Clinical: TELLUS: Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate (clinicaltrials.gov) - Jun 16, 2015
P2, N=36, Recruiting, Sponsor: Takeda
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Tresiba (insulin degludec) / Novo Nordisk
Trial primary completion date: A Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba (clinicaltrials.gov) - Jun 16, 2015
P=N/A, N=1000, Not yet recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2015 --> Aug 2017
- Lumigan (bimatoprost) / Senju, AbbVie
Enrollment open, Trial initiation date: Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues (clinicaltrials.gov) - Jun 16, 2015
P3, N=20, Recruiting, Sponsor: Rabin Medical Center
Trial primary completion date: Jun 2015 --> Aug 2017 Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Nov 2014
- ||| Lemtrada (alemtuzumab) / Sanofi
Clinical: EMERALD: Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA (clinicaltrials.gov) - Jun 16, 2015
P4, N=56, Active, not recruiting, Sponsor: Genzyme, a Sanofi Company
Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Nov 2014 Recruiting --> Active, not recruiting
- Trial completion, Enrollment change: A Survey on Low Blod Sugar Among Insulin-treated Patients With Diabetes (clinicaltrials.gov) - Jun 16, 2015
P=N/A, N=7315, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=6000 --> 7315
- |||| Invokana (canagliflozin) / J&J, Daiichi Sankyo, Mitsubishi Tanabe
Trial completion: A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM) (clinicaltrials.gov) - Jun 16, 2015
P2, N=352, Completed, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed | N=6000 --> 7315 Active, not recruiting --> Completed
- ||| Biomarker, Trial completion: A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers (clinicaltrials.gov) - Jun 16, 2015
P0, N=77, Completed, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Enrollment change, Trial primary completion date: Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (clinicaltrials.gov) - Jun 15, 2015
P3, N=40, Enrolling by invitation, Sponsor: CSL Behring
Active, not recruiting --> Completed N=70 --> 40 | Trial primary completion date: Feb 2017 --> Aug 2017
- ||||| Gocovri (amantadine ER) / Supernus Pharma
New P2 trial: Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment (clinicaltrials.gov) - Jun 15, 2015
P2, N=60, Recruiting, Sponsor: Adamas Pharmaceuticals, Inc.
- ||| dimethyl fumarate / Generic mfg., aspirin / Generic mfg.
Enrollment closed, P4 data: Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Jun 15, 2015
P4, N=241, Active, not recruiting, Sponsor: Biogen
N=70 --> 40 | Trial primary completion date: Feb 2017 --> Aug 2017 Recruiting --> Active, not recruiting
- Trial primary completion date: Screening of Subjects With Type I Diabetes to Determine Eligibility for Islet Transplantation (clinicaltrials.gov) - Jun 15, 2015
P=N/A, N=600, Recruiting, Sponsor: Rodolfo Alejandro
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2016 --> Apr 2018
- Trial primary completion date: Steroid-free and Long-term Calcineurin-free Trial in Islet Cell Transplantation (clinicaltrials.gov) - Jun 15, 2015
P2, N=12, Active, not recruiting, Sponsor: Rodolfo Alejandro
Trial primary completion date: Apr 2016 --> Apr 2018 Trial primary completion date: Dec 2015 --> Dec 2016
- Trial primary completion date: Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation (clinicaltrials.gov) - Jun 15, 2015
P2, N=20, Active, not recruiting, Sponsor: Rodolfo Alejandro
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- ||| dimethyl fumarate / Generic mfg.
Trial initiation date, Trial primary completion date: TECNERGY: Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate (clinicaltrials.gov) - Jun 15, 2015
P4, N=320, Not yet recruiting, Sponsor: Biogen
Trial primary completion date: Dec 2015 --> Dec 2016 Initiation date: May 2014 --> Jun 2015 | Trial primary completion date: Nov 2015 --> Jun 2017
- rHIgM22 / Acorda
Enrollment open: An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse (clinicaltrials.gov) - Jun 15, 2015
P1, N=30, Recruiting, Sponsor: Acorda Therapeutics
Initiation date: May 2014 --> Jun 2015 | Trial primary completion date: Nov 2015 --> Jun 2017 Not yet recruiting --> Recruiting
- | Trial completion: Diabetes Telemedicine Consultation: A Systems Improvement Intervention (clinicaltrials.gov) - Jun 13, 2015
P=N/A, N=304, Completed, Sponsor: Department of Veterans Affairs
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- New trial: Translation, Cross-cultural Adaptation and Validation of the MGQOL-15-F (clinicaltrials.gov) - Jun 12, 2015
P=N/A, N=120, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
- Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Trial primary completion date: Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. (clinicaltrials.gov) - Jun 12, 2015
P2, N=7, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
Active, not recruiting --> Completed Trial primary completion date: Mar 2015 --> Dec 2015
- Enrollment change, Trial withdrawal: Acceptability and Feasibility of an ACT-Based Group to Improve Diabetes Self-Management (clinicaltrials.gov) - Jun 12, 2015
P1/2, N=0, Withdrawn, Sponsor: Duke University
Trial primary completion date: Mar 2015 --> Dec 2015 N=45 --> 0 | Not yet recruiting --> Withdrawn
- | Afrezza (recombinant human insulin inhalation) / MannKind
New P1 trial: Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Jun 12, 2015
P1, N=30, Not yet recruiting, Sponsor: Sanofi
- Trial primary completion date: MCS-III-MOB: Psychometric Properties Mobility Measures MS (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=300, Recruiting, Sponsor: Hasselt University
N=45 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: Apr 2015 --> Sep 2015
- Trial primary completion date: Treating Foot Drop in People With Multiple Sclerosis Using Electrical Stimulation (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=10, Recruiting, Sponsor: University of Manitoba
Trial primary completion date: Apr 2015 --> Sep 2015 Trial primary completion date: Dec 2015 --> Apr 2016
- Trial primary completion date: TheraFast: Effects of Fasting on Self Efficacy (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=120, Recruiting, Sponsor: Universität Duisburg-Essen
Trial primary completion date: Dec 2015 --> Apr 2016 Trial primary completion date: Mar 2015 --> Jul 2015
- |||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Trial primary completion date: A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs) (clinicaltrials.gov) - Jun 11, 2015
P3, N=150, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Mar 2015 --> Jul 2015 Trial primary completion date: May 2016 --> Aug 2016
- Trial primary completion date: CTSM: Effects of the Cross-Training in Patients With Multiple Sclerosis (clinicaltrials.gov) - Jun 11, 2015
P1/2, N=45, Recruiting, Sponsor: Università degli Studi di Sassari
Trial primary completion date: May 2016 --> Aug 2016 Trial primary completion date: Nov 2014 --> Sep 2015
- |||| Remaloce (infliximab biosimilar) / Yuhan Corp, Biogen, Ewopharma, Merck (MSD), Samsung
Trial primary completion date: A Study Comparing SB2 to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - Jun 11, 2015
P3, N=584, Active, not recruiting, Sponsor: Samsung Bioepis Co., Ltd.
Trial primary completion date: Nov 2014 --> Sep 2015 Trial primary completion date: Aug 2014 --> Nov 2014
- |||| dalfampridine / Generic mfg.
Trial primary completion date: A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis (clinicaltrials.gov) - Jun 11, 2015
P3, N=128, Recruiting, Sponsor: Biogen
Trial primary completion date: Aug 2014 --> Nov 2014 Trial primary completion date: Apr 2016 --> Oct 2015
- Kineret (anakinra) / SOBI
Trial primary completion date: Anti-IL-1 Treatment in Children Diabetic Keto-Acidosis (DKA) at Diagnosis of Type 1 Diabetes (clinicaltrials.gov) - Jun 11, 2015
P2, N=21, Recruiting, Sponsor: University of Colorado, Denver
Trial primary completion date: Apr 2016 --> Oct 2015 Trial primary completion date: Nov 2014 --> Nov 2015
- rofecoxib (TRM-201) / Tremeau Pharma
Trial primary completion date: 12-Week No-Rofecoxib Plus Aspirin Endoscopy Study (0782-003) (clinicaltrials.gov) - Jun 11, 2015
P2, N=49, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Nov 2014 --> Nov 2015 Trial primary completion date: Aug 2005 --> Nov 2004
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial primary completion date: High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study (clinicaltrials.gov) - Jun 11, 2015
P2, N=25, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Aug 2005 --> Nov 2004 Trial primary completion date: Apr 2015 --> Aug 2015
- Cosentyx (secukinumab) / Novartis
Trial termination: Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis (clinicaltrials.gov) - Jun 11, 2015
P2, N=28, Terminated, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Apr 2015 --> Aug 2015 Completed --> Terminated; Study terminated early based upon development of another anti-IL17 fully human monoclonal antibody with better potential for treating MS patients
- || Trial initiation date, Trial primary completion date: Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=1920, Recruiting, Sponsor: University of California, San Francisco
Completed --> Terminated; Study terminated early based upon development of another anti-IL17 fully human monoclonal antibody with better potential for treating MS patients Initiation date: Aug 2010 --> Oct 2011 | Trial primary completion date: Apr 2016 --> Apr 2017
- Enrollment change, Trial initiation date, Trial primary completion date: Developing and Testing a Comprehensive MS Spasticity Management Program (clinicaltrials.gov) - Jun 11, 2015
P2, N=60, Not yet recruiting, Sponsor: Department of Veterans Affairs
Initiation date: Aug 2010 --> Oct 2011 | Trial primary completion date: Apr 2016 --> Apr 2017 N=50 --> 60 | Initiation date: Jul 2014 --> Jul 2015 | Trial primary completion date: Jan 2015 --> Dec 2015
- Rebif (human IFN-β-1a) / EMD Serono
Enrollment change, Trial termination, Trial primary completion date: RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate (clinicaltrials.gov) - Jun 11, 2015
P4, N=1, Terminated, Sponsor: EMD Serono
N=50 --> 60 | Initiation date: Jul 2014 --> Jul 2015 | Trial primary completion date: Jan 2015 --> Dec 2015 N=90 --> 1 | Recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Apr 2015; recruitment challenges
- methylprednisolone oral / Generic mfg.
Clinical: Study to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse (clinicaltrials.gov) - Jun 11, 2015
P4, N=48, Recruiting, Sponsor: Germans Trias i Pujol Hospital
N=90 --> 1 | Recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Apr 2015; recruitment challenges N=28 --> 48 | Trial primary completion date: May 2015 --> Nov 2015
- Enrollment open: Examining the Immunological Process of Autoimmune Patients (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=200, Recruiting, Sponsor: University of Florida
N=28 --> 48 | Trial primary completion date: May 2015 --> Nov 2015 Not yet recruiting --> Recruiting